Know Cancer

forgot password

A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)

Phase 1
18 Years
Not Enrolling
Myelodysplastic Syndromes

Thank you

Trial Information

A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)

Inclusion Criteria:

- Provide signed, written informed consent.

- Be at least 18 years old.

- Have a pathologically confirmed MDS and score according to the IPSS at study entry.
Pathologic confirmation is the responsibility of the investigator.

- Have been treated previously for MDS as follow: a.Patients must have had at least 1,
but no more than 2, prior treatment regimens; b.Patients must not have refractory
(i.e., disease progression or no evidence of response while on treatment) to more
than 1 prior treatment regimen.

- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Be able to comply with study procedures and follow-up examinations.

- Have adequate hepatic and renal function.

- Be non-fertile or agree to use birth control during the study through the end of the
last treatment visit and at least 90 days after.

Exclusion Criteria:

- Have had a readjustment of dose and/or schedule of erythropoietin, granulocyte colony
stimulating factor(G-CSF) or other growth factors within 8 weeks prior to the first
dose of oral clofarabine.

- Have had any other chemotherapy or any investigational therapy for MDS within 4 weeks
of the first dose of oral clofarabine.

- Have not recovered to ≤ Grade 2 in severity of any drug-related non-hematologic
toxicity prior to the first dose of oral clofarabine.

- Have an uncontrolled systemic fungal, bacterial, viral or other infection. Have a
history of serious disease involving the heart.

- Have a clinically significant cardiac assessment at screening or a known family
history QT prolongation.

- Currently uses a medication known to prolong the QT interval.

- Have had any prior treatment with clofarabine (IV or oral).

- Have had a diagnosis of another malignancy, unless the patient has been disease free
for at least 3 years after completing curative intent therapy except for the
following: a. Patients with treated non-melanoma skin cancer, in situ carcinoma, or
cervical intraepithelial neoplasia, regardless of the disease-free duration, are
eligible for this study if definitive treatment or the condition has been completed.
b. Patients with organ-confined prostate cancer with no evidence of recurrent or
progressive disease based on prostate specific antigen (PSA) values are also eligible
for this study if hormonal therapy has been initiated or a radical prostatectomy has
been performed.

- Have prior positive test for the human immunodeficiency virus (HIV).

- Have gastrointestinal disease or prior surgery, which may affect the ability of the
patient to absorb oral clofarabine.

- Is currently participating in another concurrent investigational protocol that is not
restricted to data and/or sample collection for patient demographic and/or disease

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated dose levels

Outcome Time Frame:

First Cycle

Safety Issue:


Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

September 2008

Completion Date:

October 2011

Related Keywords:

  • Myelodysplastic Syndromes
  • Oral Clofarabine,
  • relapsed/refractory MDS,
  • Myelodysplastic
  • Myelodysplastic Syndromes
  • Preleukemia



Cancer Care Centers of South TexasSan Antonio, Texas  78229
Malignant Hematology Administration, H. Lee Moffitt Cancer CenterTampa, Florida  
Division of Hematology Mayo ClinicRochester, Minnesota